Compare Cintas Corporation (CTAS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Zoetis Inc — how do they compare? Cintas Corporation trades at $202.41 (market cap $79.86B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Cintas Corporation is far larger — about 2.6× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and Zoetis Inc for 70 Days on average.
| CTAS | ZTS | |
|---|---|---|
Market Cap | $79.86B | $30.20B |
Volume | 1,323,583 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $216.53 | $147.53 |
52-Week Low | $163.55 | $69.09 |
Typical Hold Time | 125 Days | 70 Days |
Enterprise Value | $82.33B | $37.76B |
Dividend Yield | 1.03% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.12, up 1.99% today, with strong technical momentum above key support levels. The company demonstrates robust fundamentals with Q1 2027 revenue exceeding $3 billion for the first time, 10.9% organic growth, and raised fiscal 2027 guidance. Profit margins remain industry-leading with 50.99% gross margin and 17.82% net income margin, though valuation metrics appear elevated with a P/E of 39.67.
The outlook remains positive with consistent earnings beats and strong analyst support, though high valuation multiples and competitive pressures present risks. With 40% of analysts maintaining buy ratings and a consensus price target of $234.60 representing 16.6% upside, the stock offers growth potential but requires monitoring of margin sustainability and market multiple compression risks.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
